BidaskClub upgraded shares of Inotek Pharmaceuticals (NASDAQ:ITEK) from a buy rating to a strong-buy rating in a research note issued to investors on Friday morning.
Separately, Zacks Investment Research downgraded Inotek Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, September 12th.
Shares of Inotek Pharmaceuticals (NASDAQ ITEK) traded down $0.16 during midday trading on Friday, reaching $3.04. The company’s stock had a trading volume of 394,100 shares, compared to its average volume of 753,067. The company has a debt-to-equity ratio of 0.97, a quick ratio of 27.63 and a current ratio of 27.63. The firm has a market capitalization of $342.73 and a P/E ratio of -0.55. Inotek Pharmaceuticals has a 12-month low of $0.85 and a 12-month high of $3.80.
COPYRIGHT VIOLATION NOTICE: This article was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.com-unik.info/2018/01/08/inotek-pharmaceuticals-itek-upgraded-at-bidaskclub.html.
About Inotek Pharmaceuticals
Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism.
Receive News & Ratings for Inotek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inotek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.